Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NYSE:MRK

Merck & Company (MRK)

114.20
+0.33 (0.29%)
as of Jun 18, 2026, 11:15:03 pm Market Open.
161 watching
0
DON'T BUY
Pharmaceuticals may be re-establishing themselves for market leadership. Prefers Lily and Abbot
DON'T BUY
Has been a defensive stock. Overvalued.
DON'T BUY
Patent expiries are a concern. Limited pipeline. Arthritis drug not moving well. Prefers Pfizer.
BUY
Likes both Pfizer and Merck in pharmaceuticals.
BUY
Just came off a good technical support.
BUY
Good, but has some patent expiries.
DON'T BUY
Not a fan at this time. Patent expiries coming up. Prefers Pfizer.
WEAK BUY
Outlook for health care is good. Maybe a little expensive but a good long term hold.
BUY
Have been selling at $90. Prefers Pfizer
SELL
Drugs now coming off patents so future may be weaker
BUY
Expect Bush as president will be positive for US drug sector
BUY
lower valuation and better growth than AMD
Showing 241 to 252 of 252 entries